Repurposed Medicines: A Scan of the Non‐commercial Clinical Research Landscape
2024

Repurposed Medicines: A Scan of the Non‐commercial Clinical Research Landscape

Sample size: 528 publication Evidence: moderate

Author Information

Author(s): Akinbolade Sola, Fairbairn Ross, Inskip Alex, Potter Rhiannon, Oliver Aoife, Craig Dawn

Primary Institution: National Institute for Health and Care Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences Newcastle University

Hypothesis

This paper aims to provide horizon scanning intelligence on repurposed medicines evaluated by non‐commercial organizations.

Conclusion

The scan identified 528 technologies for repurposed medicines, highlighting opportunities for further research to improve patient health outcomes.

Supporting Evidence

  • The scan reported a total of 528 technologies classified by their characteristics and targeted therapeutic indications.
  • 402 technologies were solely sponsored by non-commercial organizations, while 126 were in collaboration with industry.
  • Most technologies aimed at non-cancer treatments were in later stages of clinical trials.

Takeaway

Researchers are looking at old medicines to find new ways to help people who are sick, which can be faster and cheaper than making new medicines.

Methodology

The study involved horizon scanning of clinical trial registries to identify repurposed medicines being investigated for new therapeutic indications.

Potential Biases

Industry involvement in non-commercial trials cannot be definitively ruled out, which may affect the outcomes.

Limitations

The study may have omissions due to the manual, semi-automated, and automated screening processes used.

Digital Object Identifier (DOI)

10.1002/prp2.70049

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication